Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine.

TitleCirculating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine.
Publication TypeJournal Article
Year of Publication2022
AuthorsFrancini E, Fanelli GNicolò, Pederzoli F, Spisak S, Minonne E, Raffo M, Pakula H, Tisza V, Scatena C, Naccarato AGiuseppe, Loda M, Nuzzo PVitale
JournalCancers (Basel)
Date Published2022 Sep 07

Tumor biopsy is still the gold standard for diagnosing and prognosis renal cell carcinoma (RCC). However, its invasiveness, costs, and inability to accurately picture tumor heterogeneity represent major limitations to this procedure. Analysis of circulating cell-free DNA (cfDNA) is a non-invasive cost-effective technique that has the potential to ease cancer detection and prognosis. In particular, a growing body of evidence suggests that cfDNA could be a complementary tool to identify and prognosticate RCC while providing contemporary mutational profiling of the tumor. Further, recent research highlighted the role of cfDNA methylation profiling as a novel method for cancer detection and tissue-origin identification. This review synthesizes current knowledge on the diagnostic, prognostic, and predictive applications of cfDNA in RCC, with a specific focus on the potential role of cell-free methylated DNA (cfMeDNA).

Alternate JournalCancers (Basel)
PubMed ID36139519
PubMed Central IDPMC9497114
Related Faculty: 
Massimo Loda, M.D. Pier Nuzzo, Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700